Skip to content

Author

F. Clarelli

We have 3 of 70 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Anti‐CD20 Drugs and Natalizumab Confer Equal Protection Against Progression Independent of Relapse Activity (PIRA) in People With Multiple Sclerosis

Highly effective (HE) disease‐modifying therapies (DMTs) reduce relapse‐associated worsening (RAW) and progression independent of relapse activity (PIRA). Natalizumab (NTZ) and anti‐CD20 agents show similar efficacy on relapse suppression, but long‐term comparative data on PIRA are limited. We aimed to compare PIRA acc...

L. Palazzo, F. Clarelli, Michele Surano et al. · 0 citations
Sep 2026

Imaging subtypes reveal distinct biological substrates and disability profiles in multiple sclerosis.

Multimodal MRI analysed with SuStaIn identified reproducible subtypes of multiple sclerosis with clinically meaningful differences in phenotype, age at onset, disability, and relapse-independent progression, while cognitive impairment was related to advancing SuStaIn stage within each subtype.

P. Preziosa, L. Storelli, F. Clarelli et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.